These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34168283)

  • 1. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
    Wierda WG; Rawstron A; Cymbalista F; Badoux X; Rossi D; Brown JR; Egle A; Abello V; Cervera Ceballos E; Herishanu Y; Mulligan SP; Niemann CU; Diong CP; Soysal T; Suzuki R; Tran HTT; Wu SJ; Owen C; Stilgenbauer S; Ghia P; Hillmen P
    Leukemia; 2021 Nov; 35(11):3059-3072. PubMed ID: 34168283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Italian Cytometry Society (GIC) endorsement of consensus recommendations for measurable residual disease in chronic lymphocytic leukemia.
    D'Arena G; Volpe S; Amodeo R; Tirino V; D'Auria F; Annamaria G; Pietrantuono G; Laurenti L; Aiello A; Musto P
    Int J Lab Hematol; 2022 Jun; 44(3):e120-e122. PubMed ID: 34796668
    [No Abstract]   [Full Text] [Related]  

  • 3. Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
    Al-Sawaf O; Seymour JF; Kater AP; Fischer K
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):775-791. PubMed ID: 34102145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
    García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
    Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.
    Rios-Olais FA; Hilal T
    Curr Treat Options Oncol; 2023 Aug; 24(8):907-928. PubMed ID: 37195588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
    Cheson BD; Mato AR
    Clin Adv Hematol Oncol; 2020 Jun; 18 Suppl 10(6):1-20. PubMed ID: 33843867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing minimal residual disease in chronic lymphocytic leukemia.
    Rawstron AC; Hillmen P
    Curr Hematol Malig Rep; 2008 Jan; 3(1):47-53. PubMed ID: 20425446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
    Letestu R; Dahmani A; Boubaya M; Baseggio L; Campos L; Chatelain B; Debliquis A; Drénou B; Jacob MC; Legac E; Le Garff-Tavernier M; Lhoumeau AC; Quiney C; Robillard N; Ticchioni M; Aanei C; Katsahian S; Delepine R; Vaudaux S; Rouillé V; Béné MC; Dartigeas C; Van Den Neste E; Leprêtre S; Feugier P; Cartron G; Leblond V; Lévy V; Cymbalista F;
    Leukemia; 2021 Jun; 35(6):1597-1609. PubMed ID: 32934355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of Minimal Residual Disease in Chronic Lymphocytic Leukemia].
    Doubek M
    Klin Onkol; 2015; 28 Suppl 3():3S16-21. PubMed ID: 26489497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurable residual disease in the treatment of chronic lymphocytic leukemia.
    Uchiyama T; Yokoyama A; Aoki S
    J Clin Exp Hematop; 2020 Dec; 60(4):138-145. PubMed ID: 33148932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearly defined response criteria evaluating treatment of CLL patients in clinical research trials.
    Foon KA
    Blood; 2010 Sep; 116(10):1817; author reply 1817-8. PubMed ID: 20829381
    [No Abstract]   [Full Text] [Related]  

  • 13. Eradication of minimal residual disease in chronic lymphocytic leukemia.
    Schweighofer CD; Hallek M; Wendtner CM
    Curr Hematol Malig Rep; 2008 Jan; 3(1):54-60. PubMed ID: 20425447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?
    Yang S; Kay NE; Shi M; Ossenkoppele G; Walter RB; Gale RP
    Leukemia; 2021 Dec; 35(12):3364-3370. PubMed ID: 34580401
    [No Abstract]   [Full Text] [Related]  

  • 15. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
    Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
    Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
    Hallek M; Cheson BD; Catovsky D; Caligaris-Cappio F; Dighiero G; Döhner H; Hillmen P; Keating M; Montserrat E; Chiorazzi N; Stilgenbauer S; Rai KR; Byrd JC; Eichhorst B; O'Brien S; Robak T; Seymour JF; Kipps TJ
    Blood; 2018 Jun; 131(25):2745-2760. PubMed ID: 29540348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of minimal residual disease in chronic lymphocytic leukemia.
    Al-Sawaf O; Hallek M; Fischer K
    Clin Adv Hematol Oncol; 2022 Feb; 20(2):97-103. PubMed ID: 35120090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients.
    Brett VE; Dilhuydy MS; Lechevalier N; Adjibabi AN; Gros FX; Forcade É; Letestu R; Vial JP
    Ann Biol Clin (Paris); 2023 Oct; 81(4):379-387. PubMed ID: 37864443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
    Chen X; Chen X; Zhao S; Shi Y; Zhang N; Guo Z; Qiao C; Jin H; Zhu L; Zhu H; Li J; Wu Y
    Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
    Owen C; Christofides A; Johnson N; Lawrence T; MacDonald D; Ward C
    Leuk Lymphoma; 2017 Dec; 58(12):2777-2785. PubMed ID: 28509580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.